Candel Therapeutics (CADL) Gross Profit: 2020-2023
Historic Gross Profit for Candel Therapeutics (CADL) over the last 4 years, with Dec 2023 value amounting to $4.5 million.
- Candel Therapeutics' Gross Profit rose 14470.97% to $4.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $2.6 million, marking a year-over-year increase of 1992.74%. This contributed to the annual value of $2.1 million for FY2024, which is 19.46% down from last year.
- Latest data reveals that Candel Therapeutics reported Gross Profit of $4.5 million as of Q4 2023, which was up 775.19% from -$669,000 recorded in Q3 2023.
- Candel Therapeutics' 5-year Gross Profit high stood at $4.5 million for Q4 2023, and its period low was -$669,000 during Q3 2023.
- In the last 3 years, Candel Therapeutics' Gross Profit had a median value of $31,000 in 2022 and averaged $236,917.
- Within the past 5 years, the most significant YoY rise in Candel Therapeutics' Gross Profit was 14,470.97% (2023), while the steepest drop was 2,258.06% (2023).
- Over the past 4 years, Candel Therapeutics' Gross Profit (Quarterly) stood at $31,000 in 2020, then remained steady at $31,000 in 2021, then remained steady at $31,000 in 2022, then surged by 14,470.97% to $4.5 million in 2023.
- Its last three reported values are $4.5 million in Q4 2023, -$669,000 for Q3 2023, and -$644,000 during Q2 2023.